newsfilter
← Latest News
GlobeNewswire·

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study